| Autor: |
Boyce TG; Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. thomas.boyce@mcmail.vanderbilt.edu, Gruber WC, Coleman-Dockery SD, Sannella EC, Reed GW, Wolff M, Wright PF |
| Jazyk: |
angličtina |
| Zdroj: |
Vaccine [Vaccine] 1999 Aug 20; Vol. 18 (1-2), pp. 82-8. |
| DOI: |
10.1016/s0264-410x(99)00183-8 |
| Abstrakt: |
Intranasal trivalent, cold-adapted, live attenuated influenza vaccine (CAIV-T) is a promising alternative to inactivated vaccine for protection against influenza in children. However, correlates of immunity are not well defined. To determine the mucosal immune response to CAIV-T, 19 children ages 15-55 months were randomized to receive two doses of CAIV-T or placebo. Influenza-specific IgA to the haemagglutinin of each of three contemporary strains was measured in nasal washes collected pre- and postvaccination using a kinetic enzyme-linked immunosorbent assay. After two doses of study drug, 62, 69 and 85% of CAIV-T recipients demonstrated a mucosal IgA response to influenza A/H1N1, A/H3N2, and B strains respectively; in comparison, 33, 0 and 17% of placebo recipients demonstrated an IgA response to the same strains (p = 0.35, 0.01 and 0.01). Overall, seropositive vaccinees were 4.5 times more likely to develop a mucosal immune response than an HAI response (p = 0.015). Two doses of CAIV-T induce a mucosal IgA response to all three influenza vaccine antigens in the majority of children. In addition, a mucosal antibody response may be the only indication of a vaccine take in a seropositive child. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect